Abstract | WHAT IS KNOWN AND OBJECTIVE: CASE SUMMARY: WHAT IS NEW AND CONCLUSION: The combination of IFNB-1b therapy and melilot supplement intake may cause severe liver dysfunction in patients with MS. Given the doubtful value of the supplement, we suggest that it should be avoided by patients receiving interferon therapy.
|
Authors | S Tamura, Y Warabi, S Matsubara |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 37
Issue 6
Pg. 724-5
(Dec 2012)
ISSN: 1365-2710 [Electronic] England |
PMID | 22642738
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Adjuvants, Immunologic
- Coumarins
- Drug Combinations
- Resins, Plant
- Interferon beta-1b
- Rutin
- Interferon-beta
- coumarin, resin, rutin, volatile oil drug combination
- Aspartate Aminotransferases
- Alanine Transaminase
|
Topics |
- Adjuvants, Immunologic
(administration & dosage, adverse effects, therapeutic use)
- Alanine Transaminase
(metabolism)
- Aspartate Aminotransferases
(metabolism)
- Chemical and Drug Induced Liver Injury
(etiology, physiopathology)
- Coumarins
(administration & dosage, adverse effects)
- Drug Combinations
- Female
- Herb-Drug Interactions
- Humans
- Injections, Intramuscular
- Injections, Subcutaneous
- Interferon beta-1b
- Interferon-beta
(administration & dosage, adverse effects, therapeutic use)
- Multiple Sclerosis
(drug therapy)
- Resins, Plant
(administration & dosage, adverse effects)
- Rutin
(administration & dosage, adverse effects)
- Severity of Illness Index
- Young Adult
|